contrarian168

contrarian168 | Joined since 2016-01-26

Investing Experience -
Risk Profile -

Followers

0

Following

0

Blog Posts

0

Threads

19

Blogs

Threads

Portfolio

Follower

Following

Summary
Total comments
19
Past 30 days
0
Past 7 days
0
Today
0

User Comments
Stock

2019-11-22 12:34 | Report Abuse

@Jeffreyteck

alots more mystery inside this company,pls check how may units of house is sold for the whole years ,hahah

Stock

2019-11-22 12:21 | Report Abuse

tiger 0.075 come back to the square

Stock

2019-11-22 10:02 | Report Abuse

wow,as expected,those had bought last fews days as you are help big boy clear some of its debts,stuck today,lets tell u next target is RM 0.075,fast run before its reach

Stock

2019-11-20 15:56 | Report Abuse

today t1,yesterday bought retailer is coming out to throw to u,expect today close lower than RM0.09

Stock

2019-11-20 15:03 | Report Abuse

ya,faster buy so u can help the big boy clear some of its debt!

Stock

2019-11-20 14:47 | Report Abuse

Again dont easier get trap by this company,retailer always get crazy when the big boy pull up the price

Stock

2017-06-09 09:28 | Report Abuse

JFtech PE ratio 59,ROE 14.61
inari PE ratio 20. ROE 24.32

price looks expensive,dont be greedy,the price shoot up because of the day trader long and short

Stock

2016-08-11 15:04 | Report Abuse

5 Malaysian firms on Forbes Asia ‘Best Under A Billion’ list

Inari Amertron Bhd

Stock

2016-08-11 15:02 | Report Abuse

KUALA LUMPUR: Five Malaysian companies, including new entrant Karex Bhd, the world’s largest manufacturer of condoms, made it to the 2016 Forbes Asia’s “Best Under A Billion” list.

The other companies are semiconductor player Inari Amerton Bhd, construction company Mitrajaya Holdings Bhd, MY E.G. Services Bhd (MyEG) and Signature International Bhd.

The “Best Under A Billion” list honours 200 leading public companies in the Asia Pacific region with annual revenue between US$5mil and US$1bil, have positive net income and have been publicly traded for at least a year.

Forbes said from a universe of 17,000 companies, the candidates were screened on sales growth and earnings growth in the past 12 months and over three years, and for the strongest five-year return on equity.

Below is the statement issued by Forbes Asia:

Companies from mainland China, Hong Kong and Taiwan account for 65% of this year’s Forbes Asia’s “Best Under A Billion” list, a record high for the list of the top 200 publicly traded companies in the Asia-Pacific region. Of the 200 companies, 116 are new on this year’s list. The full list can be found at www.forbes.com/bub and in the latest issue of Forbes Asia.

The “Best Under A Billion” list honors 200 leading public companies in the Asia Pacific region with annual revenue between US$5 million and $1 billion, have positive net income and have been publicly traded for at least a year.

From a universe of 17,000 companies, the candidates are screened on sales growth and earnings growth in the past 12 months and over three years, and for the strongest five-year return on equity.

A total of 98 companies from China and Hong Kong made it to this year’s list, up from 84 the previous year. These companies stand out not just because of their record number but because they largely defy those who think that the world’s second largest economy is in trouble.

Companies that made the list include East Money Information, the most-visited financial website in the world; environmental tech company Beijing Sanju Environmental Protection and New Material; drama production company Zhejiang Huace Film & TV; cosmetics producer Shanghai Jahwa United; paint material manufacturer Beijing Oriental Yuhong Waterproof Technology and elevator equipment producer Canny Elevator.

A sector that has consistently stood out in recent years is biopharmaceuticals in China. This year, a total of 17 such companies made the list, including those associated with herbals or traditional Chinese medicine.

China’s lifting of price caps for most of the drug types in June 2015, also fueled the pharmaceutical and biotech sector’s growth. A notable listee is China Biologic Products, whose value has held steady. This year marks the fifth time the human plasma-based biopharmaceutical company made the list.

Making a strong showing on the list is Taiwan with 32 companies. Returning listees include KMC (Kuei Meng) International, the world’s biggest maker of bicycle chains, and TOPBI International Holdings, maker of children’s apparels and accessories.

South Korea has 16 companies on this year’s list, including LOEN Entertainment, an online music sales and talent development company. Japan made a strong rebound with 13 companies, an increase from eight last year. MonotaRO, a Japanese company which sells factory supplies and replacement parts online, also returns to the list.

Elsewhere in the region, Australia, India and Pakistan have seven companies each. A notable listee is Australian gold mining firm, Northern Star Resources, which has made a dramatic recovery from a near meltdown a decade ago with a huge comeback of $2.1 billion in market value. Sri Lanka has three companies on this year’s list, up from one last year.

In Southeast Asia, Singapore has two companies on this year’s list, while Malaysia has five companies, which includes new entrant Karex, the world’s largest manufacturer of condoms.

Thailand has four including Forth Smart Service, a top-up service company for prepaid phone and bankcards, while Vietnam has five companies on the list. The sole listee from the Philippines this year is D&L Industries, producer of food ingredients, plastics and chemicals. Indonesia has no representation on this year’s list.

Tim Ferguson, Editor of Forbes Asia, said: “Even if the Chinese economy continues to slow, the rest of Asia—if it is to carve out a bigger place on this SME all-star list—is going to find big markets for high-value goods and services. Maybe the Asean trade treaties can help.”

Stock

2016-08-11 12:31 | Report Abuse

Inari-Amertron

We visited Inari-Amertron's newest production plants, P13 and P21, which are
also located in Bayan Lepas, Penang. The visit started with a briefing on the
company’s latest developments and outlook for 2H16, followed by a tour of the
facilities. The meeting was hosted by Group CEO K.C. Lau. The key takeaways
from the meeting are below:

1) Management maintains its guidance of 15% qoq revenue growth in
4QFY6/16, driven by recovery in RF component demand ahead of new
smartphones launches in 2HCY16. The group’s utilisation rate hovered at
70% in Jul, higher than the 60% in 3QFY16.

2) Inari plans to raise RF tester capacity from 700 units in Jul to 900 by
1HCY17. Effectively this would raise the group’s RF testing capacity by
30% in FY17. The additional testers would be deployed at P13 and P21.

3) We are impressed by management’s ability to improve operations at its
newly-acquired plant P21, getting it ready for production two months after
taking over the vacant facility in May 2016. To recap, P21 will house the
newly-formed Inari Integrated Systems (IISB) division, which will focus on
test development, product engineering, wafer probe and package tests.
Management expects IISB to contribute revenue of RM70m-80m or 6-7%
of group revenue in FY17.

4) P21 has commenced operations, with two testers running in end-July and it
expects to add about two testers per week over the next six months. This
would effectively raise total capacity to about 58 testers by 3QFY17. We
are encouraged by this, as it demonstrates that Inari is starting to benefit
from the Avago-Broadcom merger and that it has successfully ventured
into enterprise and network infrastructure chip testing, diversifying its
exposure beyond smartphones.

5) Management also shared that Inari is in discussions with its partner PCL
Technologies to finalise the location of their new facility in China.
Management expects the new facility to be ready in 2H17. We like
management’s strategy of capitalising on its expertise in RF testing to
expand in China as this would diversify its earnings and address investors’
concerns about Inari’s customer concentration in Broadcom.

6) There were no surprises from the visit but we foresee an exciting earnings
outlook for Inari in FY17, driven by resilient increase in smartphone RF
content, new IISB earnings, and stronger earnings contribution from ISL.
Management targets 18% revenue growth for FY17.

7) Overall, maintain Add rating on the stock, with an unchanged target price of
RM3.15, still based on 13x P/E, similar to sector average. We see potential
re-rating in view of higher RF content growth per smartphone, improving
industry sentiment with successful new smartphone model launches and
sustainable margin expansion at Amertron.

Stock

2016-08-11 12:30 | Report Abuse

Inari remains semiconductor sector top pick due to its strong earnings visibility, better cost
control than peers and good relationship with key customer Broadcom. Key
risks are longer smartphone replacement cycle and slowdown in global
economic recovery.

Stock

2016-05-25 11:00 | Report Abuse

dont forget the u still entitled for the free warrant ,what price u think warrant can go??

Stock

2016-05-25 10:29 | Report Abuse

Prolexus’ revenue comes mostly from the export market, with the United States (59%) and Europe (19%) being the biggest revenue contributors in the last financial year ended July 31, 2015.

u think ringgit will weaken or strengthen in next 3 months??

Stock

2016-05-25 10:14 | Report Abuse

still remember bimb -wa jump up continuos for first 3 days??
i expect warrant will go from 0.4 to 0.5
plus the conversion RM1 adn the price now RM.86,
you will have RM2.26 in the pocket,good deal ???

Stock

2016-05-25 09:35 | Report Abuse

ringgit weaken will benefited for this company;

http://www.investing.com/currencies/usd-myr
4.1195 +0.0130 +0.32%
01:32:42 GMT - Real-time Data. ( Disclaimer )

by the coming TPPA,this company will enjoy the free tax scheme again,last catalyst,olympic coming,u think nike shirt will get the better sales??

Stock

2016-05-25 09:29 | Report Abuse

existing 2 mother entitled one right and free one warrant
by buying the right shares in the open market is a good strategy on arbitrage
right shares price .865,plus RM 1 to convert to mother ,with the expected free warrant price with RM0.4-0.50,so total u will get RM2.26 by compare mother only RM1.5,good deal,???